ClinicalTrials.gg
CompletedNCT04999839Updated Sep 28, 2023Results posted

Study of NDI-034858 in Participants With Moderate to Severe Plaque Psoriasis

A Phase 2 interventional study of NDI-034858 study drug and NDI-034858 study drug in Moderate to Severe Plaque Psoriasis, sponsored by Takeda. Completed at 69 sites in 2 countries. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2023-09-28.

Sponsored by Takeda · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
259
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 764 studies in Psoriasis with a site in United States — 55 open to participants now, 86 under way, 19 of them phase 3. Psoriasis · United States.

Enrollment
166th of 673
259 · median 77
Started
2021
with 37 others
Phase 2
200 of 764
5 open now
Registered
622nd of 764
by date

Among the 764 studies in Psoriasis with a site in United States, this one is the 166th largest by enrollment of the 673 interventional ones that give a count, is one of 38 that started in 2021, is one of 200 in phase 2, and was the 622nd registered.

Psoriasis

2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.

Browse Psoriasis studies →

Open to participants now

55 of the 764 studies in Psoriasis with a site in United States are open now. Recruiting first, the newest first:

50 more — sign in →

All 55 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 764 studies in Psoriasis with a site in United States, or all of them as a file.
02

Study summary

This is a Phase 2b, randomized, multicenter, double-blind, placebo-controlled, multiple-dose study designed to evaluate the efficacy, safety, and tolerability of NDI-034858 in participants with moderate to severe plaque psoriasis. This study will also evaluate the plasma concentrations of NDI-034858 and explore the immune response to NDI-034858 in participants with moderate to severe plaque psoriasis.

Read the detailed description

Approximately 259 male and female participants, aged 18 to 70 years (inclusive) were enrolled in this study. Participants were randomized to receive either one of the four doses of NDI-034858, or placebo on Day 1. The goal was to have approximately 50 participants randomized per treatment group (1:1:1:1:1 ratio) on Day 1. During the treatment period, NDI-034858 or placebo was orally administered QD for 12 weeks. The 12 week treatment period was followed by a 4-week safety follow-up period.

03

Conditions studied

  • Moderate to Severe Plaque Psoriasis

Browse trials for

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

In order to be eligible to participate in this study, a participant must meet all of the following criteria, either at the screening and Day 1 visits or only at one of the specified visits (screening or Day 1) as noted in the criterion:

  1. Male or female participant aged 18 to 70 years, inclusive, at the time of consent.
  2. Participant has a history of plaque psoriasis for at least 6 months prior to the screening visit.
  3. Participant had no significant flare in psoriasis for at least 3 months before screening (information obtained from medical chart or participant's physician, or directly from the participant).
  4. Participant has moderate to severe plaque psoriasis as defined by a PASI score ≥ 12 and a PGA score ≥ 3 at screening and Day 1.
  5. Participant has plaque psoriasis covering ≥ 10% of his or her total BSA at screening and Day 1.
  6. Participant must be a candidate for phototherapy or systemic therapy.
  7. For female participants of involved in any sexual intercourse that could lead to pregnancy: the participant must agree to use a highly effective method from at least 4 weeks prior to Day 1 until at least 4 weeks after the last study product administration. Highly effective contraceptive methods include hormonal contraceptives (eg, combined oral contraceptive, patch, vaginal ring, injectable, or implant), intrauterine devices or intrauterine systems, vasectomized partner(s) (provided vasectomy was performed ≥ 4 months prior to screening), bilateral tubal ligation or occlusion, or double barrier methods of contraception (eg, male condom with cervical cap, male condom with diaphragm, and male condom with contraceptive sponge) in conjunction with spermicide.
  8. Female participants of childbearing potential have had a negative serum pregnancy test at screening and negative urine pregnancy test at Day 1.
  9. For male participants involved in any sexual intercourse that could lead to pregnancy, participant must agree to use one of the highly effective contraceptive methods listed in Inclusion Criterion 6, from Day 1 until at least 12 weeks after the last study product administration. If the female partner of a male participant uses any of the hormonal contraceptive methods listed above, this contraceptive method should be used by the female partner from at least 4 weeks before Day 1 until at least 12 weeks after the last study product administration.
  10. Participant has a within the range of 18 to 42 kg/m2, inclusive (BMI = weight [kg]/[height (m)]2), and total body weight >50 kg (110 lb).
  11. Participant is willing to participate and is capable of giving . Note: Consent must be obtained prior to any study-related procedures.
  12. Participant must be willing to comply with all study procedures and must be available for the duration of the study.

Exclusion criteria

Exclusion Criteria:

A participant who meets any of the following criteria at the screening and/or Day 1 visits, as applicable, will be excluded from participation in this study:

  1. Participant is a female who is breastfeeding, pregnant, or who is planning to become pregnant during the study.
  2. Participant has evidence of erythrodermic, pustular, predominantly guttate psoriasis, or drug induced psoriasis.
  3. Participant has a history of skin disease or presence of skin condition that, in the opinion of the investigator, would interfere with the study assessments.
  4. Participant has immune-mediated conditions commonly associated with psoriasis, such as psoriatic arthritis, uveitis, inflammatory bowel disease, that require systemic treatment (including , , or biologics). Note: Participants with immune-mediated conditions that do not require systemic treatment may be included in the study. Certain therapies such as NSAIDs may be permitted, but should be discussed with the Medical Monitor prior to determination of participant eligibility.
  5. Participant has any medical condition, evidence of an unstable clinical condition (eg, cardiovascular, renal, hepatic, hematologic, gastrointestinal, endocrine, pulmonary, immunologic, or local active infection/infectious illness), psychiatric condition, or vital signs/physical/laboratory/ abnormality that would, in the opinion of the investigator, put the participant at undue risk or interfere with interpretation of study results.
  6. Participant had a major surgery within 8 weeks prior to Day 1 or has a major surgery planned during the study.
  7. Participant has a history of Class III or IV congestive heart failure as defined by Criteria.
  8. Participant has been hospitalized in the past 3 months for asthma, has ever required intubation for treatment of asthma, currently require oral corticosteroids for the treatment of asthma, or has required more than one short-term (≤ 2 weeks) course of oral corticosteroids for asthma within 6 months prior to Day 1.
  9. Participant has a history of cancer or lymphoproliferative disease within 5 years prior to Day 1. Participant with successfully treated non- cutaneous squamous cell or basal cell carcinoma and/or localized carcinoma in situ of the cervix are not to be excluded.
  10. Participant has a history of fever, inflammation, or systemic signs of illness suggestive of systemic or invasive infection within 4 weeks prior to Day 1.
  11. Participant has an active bacterial, viral, fungal, mycobacterial infection, or other infection (including TB or atypical mycobacterial disease), or any major episode of infection that required hospitalization or treatment with intravenous antibiotics within 12 weeks prior to Day 1, or oral antibiotics within 4 weeks prior to Day 1.
  12. Participant has a history of chronic or recurrent infectious disease, including but not limited to chronic renal infection, chronic chest infection, recurrent urinary tract infection, fungal infection (with the exception of superficial fungal infection of the nailbed), or infected skin wounds or ulcers.
  13. Participant has a history of an infected joint prosthesis or has received antibiotics for a suspected infection of a joint prosthesis, if that prosthesis has not been removed or replaced.
  14. Participant has active herpes infection, including herpes simplex 1 and 2 and herpes zoster (demonstrated on physical examination and/or medical history) within 8 weeks prior to Day 1.
  15. Participant has a history of known or suspected congenital or acquired immunodeficiency state or condition that would compromise the participant's immune status in the opinion of the investigator (eg, history of splenectomy, primary immunodeficiency).
  16. Participant has positive results for surface antigens (HBsAg), antibodies to hepatitis B core antigens (anti-HBc), virus (HCV), or (HIV).
  17. Participant has clinical or laboratory evidence of active or latent TB infection at screening.
  18. Participant with any of the following laboratory values at the screening visit:

    1. (ALT) or aspartate aminotransferase (AST) values ≥ 3 times the (ULN);
    2. \< 11.0 g/dL (\< 110.0 g/L);
    3. White blood cell count \< 3.5 x 109/L (\< 3500/mm3);
    4. of \< 1.8 x 109/L (\< 1800/mm3);
    5. Absolute lymphocyte count of \< 1.0 x 109/L (\< 1000/mm3);
    6. count \< 100 x 109/L (\< 100,000/mm3);
    7. Total ˃ 2 times the ULN.
  19. Participant who have given > 50 ml of blood or plasma within 30 days of screening or > 500 mL of blood or plasma within 56 days of screening (during a clinical study or at a blood bank donation).
  20. Participant has used any topical medication that could affect psoriasis (including corticosteroids, retinoids, vitamin D analogues [such as calcipotriol], JAK inhibitors, or tar) within 2 weeks prior to Day 1.
  21. Participant has used any systemic treatment that could affect psoriasis (including oral, intravenous, intraarticular, intrathecal, intramuscular, or intralesional corticosteroids, oral retinoids, immunosuppressive/immunomodulating medication, methotrexate, cyclosporine, oral JAK inhibitors, or apremilast) within 4 weeks prior to Day 1.
  22. Participant has received any UV-B phototherapy (including tanning beds) or excimer laser within 4 weeks prior to Day 1.
  23. Participant has had PUVA treatment within 4 weeks prior to Day 1.
  24. Participant has received any within 4 weeks prior to Day 1 or plans to receive a live-attenuated vaccine during the study and up to 4 weeks or 5 half lives of the study product, whichever is longer, after the last study product administration. Note: Nonlive-attenuated vaccines or boosters for Coronavirus Disease 2019 (COVID-19) (eg, RNA-based vaccines, inactivated adenovirus-based vaccines, protein-based vaccines) are allowed during the study. The study site should follow local guidelines related to COVID-19.
  25. Participant is currently receiving a nonbiological product or device or has received one within 4 weeks prior to Day 1.
  26. Participant has received any marketed or investigational biological agent within 12 weeks or 5 half-lives (whichever is longer) prior to Day 1 (except those listed in Exclusion Criterion 27 and 28 that are to be excluded for 6 months).
  27. Participant was previously enrolled in any study with NDI-034858.
  28. Participant has a history of lack of response to any therapeutic agent targeting IL-12, IL-17, and/or IL 23 (eg, ustekinumab, secukinumab, ixekizumab, brodalumab, guselkumab, tildrakizumab, risankizumab) at approved doses after at least 12 weeks of therapy, and/or received one of these therapies within 6 months prior to Day 1.
  29. Participant has received rituximab or other immune-cell depleting therapy within 6 months.
  30. Participant is currently being treated with strong or moderate cytochrome P450 3A () inhibitors (such as itraconazole), or has received moderate or strong CYP3A4 inhibitors within 4 weeks prior to Day 1.
  31. Participant is currently being treated with terbinafine, or has received terbinafine within 4 weeks prior to Day 1.
  32. Participant has consumed grapefruit within 1 week prior to Day 1.
  33. Participant has used tanning booths within 4 weeks prior to Day 1, has had excessive sun exposure, or is not willing to minimize natural and artificial sunlight exposure during the study.
  34. Participant has a known or suspected allergy to NDI-034858 or any component of the investigational product, or any other significant drug allergy (such as anaphylaxis or hepatotoxicity).
  35. Participant has a known history of clinically significant drug or alcohol abuse in the last year prior to Day 1.
  36. For participant consenting to collection only:

    • Participant has a history of an allergic reaction or significant sensitivity to lidocaine or other local anesthetics.
    • Participant has a history of hypertrophic scarring or keloid formation in scars or suture sites.
    • Participant has taken anticoagulant medication, such as heparin, low molecular weight (LMW)-heparin, warfarin, or antiplatelet agents (except low-dose aspirin ≤ 81 mg which will be allowed), within 2 weeks prior to Day 1, or has a to skin biopsies. Nonsteroidal anti-inflammatory drugs will not be considered antiplatelet agents and will be allowed.
Terms in these criteria, in plain language(24)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
259 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Participants received placebo matched to NDI-034858 oral capsules, once daily (QD) for up to 12 weeks.

    Other: Placebo

  • Experimental
    NDI-034858 2 milligrams (mg)

    Participants received 2 mg of NDI-034858 oral capsules, QD for up to 12 weeks.

    Drug: NDI-034858 study drug

  • Experimental
    NDI-034858 5 mg

    Participants received 5 mg of NDI-034858 oral capsules, QD for up to 12 weeks.

    Drug: NDI-034858 study drug

  • Experimental
    NDI-034858 15 mg

    Participants received 15 mg of NDI-034858 oral capsules, QD for up to 12 weeks.

    Drug: NDI-034858 study drug

  • Experimental
    NDI-034858 30 mg

    Participants received 30 mg (2\*15 mg) of NDI-034858 oral capsules, QD for up to 12 weeks.

    Drug: NDI-034858 study drug

Interventions

  • NDI-034858 2 mg oral capsules.

    Also known as: NDI-034858, TAK-279

  • NDI-034858 5 mg oral capsules.

    Also known as: NDI-034858, TAK-279

  • NDI-034858 15 mg oral capsules.

    Also known as: NDI-034858, TAK-279

  • NDI-034858 30 mg (2\*15 mg) oral capsules.

    Also known as: NDI-034858, TAK-279

  • OtherPlacebo

    Placebo matched to NDI-034858 oral capsules.

    Also known as: Non Active Ingredient

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Who Achieved at Least 75 Percent (%) Improvement From Baseline in Psoriasis Area and Severity Index (PASI-75) at Week 12

    The PASI quantifies the severity of a participant's psoriasis based on both "lesion severity" and the "percent of body surface area (BSA)" affected. PASI is a composite scoring by the investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk \[including axillae and groin\], and lower limbs \[including buttocks\]), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI composite score varies in increments of 0.1 and range from 0 (no disease) to 72 (maximal disease), with higher scores representing greater severity of psoriasis. PASI 75 response is a binary measure defined as at least a 75% improvement in PASI score at Week 12, relative to baseline PASI score.

    Time frame: Baseline, Week 12

Secondary outcomes

  1. Percentage of Participants Who Achieved Physician's Global Assessment (PGA) Score of Clear (0) or Almost Clear (1) at Week 12

    The PGA is a global assessment of the current state of the disease. It is a 5-point morphological assessment of overall disease severity with scores ranging from 0 to 4, where Score 0: Clear (No signs of psoriasis; post-inflammatory hyperpigmentation may be present); Score 1: Almost clear (No thickening; normal to pink coloration; no to minimal focal scaling); Score 2: Mild (Just detectable to mild thickening; pink to light red coloration; predominantly fine scaling); Score 3: Moderate (Clearly distinguishable to moderate thickening; dull to bright red; clearly distinguishable to moderate erythema; moderate scaling); Score 4: Severe (Severe thickening with hard edges; bright to deep dark red coloration; severe/coarse scaling covering almost all or all lesions). The percentage of participants who achieved a PGA score of clear (0) or almost clear (1) at Week 12 were reported.

    Time frame: At Week 12

  2. Percentage of Participants Who Achieved at Least 90% Improvement From Baseline in Psoriasis Area and Severity Index (PASI-90) at Week 12

    The PASI quantifies the severity of a participant's psoriasis based on both "lesion severity" and the "percent of BSA" affected. PASI is a composite scoring by the investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk \[including axillae and groin\], and lower limbs \[including buttocks\]), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI composite score varies in increments of 0.1 and range from 0 (no disease) to 72 (maximal disease), with higher scores representing greater severity of psoriasis. PASI 90 response is a binary measure defined as at least a 90% improvement in PASI score at Week 12, relative to baseline PASI score.

    Time frame: Baseline, Week 12

  3. Percentage of Participants Who Achieved at Least 100% Improvement From Baseline in Psoriasis Area and Severity Index (PASI-100) at Week 12

    The PASI quantifies the severity of a participant's psoriasis based on both "lesion severity" and the "percent of BSA" affected. PASI is a composite scoring by the investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk \[including axillae and groin\], and lower limbs \[including buttocks\]), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI composite score varies in increments of 0.1 and range from 0 (no disease) to 72 (maximal disease), with higher scores representing greater severity of psoriasis. PASI 100 response is a binary measure defined as at least a 100% improvement in PASI score at Week 12, relative to baseline PASI score.

    Time frame: Baseline, Week 12

  4. Change From Baseline in Dermatology Life Quality Index (DLQI) Total Score at Week 12

    The DLQI is a simple 10 question validated questionnaire that has been used in more than 40 different skin conditions. The DLQI is the most frequently used quality of life instrument in studies of randomized controlled trials in dermatology. Each question is scored on a four-point Likert scale: very much (3); a lot (2); a little (1); not at all (0). DLQI total score is defined as the sum of the 10 questions, ranging from 0 (not at all) to 30 (very much). Higher scores indicate more impact on quality of life of participants; and lower scores indicate less impact on the quality of life of participants.

    Time frame: Baseline, Week 12

  5. Number of Participants With Treatment-emergent Adverse Event (TEAEs) and Serious TEAEs

    An adverse event (AE) means any untoward medical occurrence in a participant administered a pharmaceutical product; the untoward medical occurrence does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product whether or not it is related to the medicinal product. TEAEs were defined as any AEs with onset date on or after the first study treatment dosing. An SAE was any untoward medical occurrence that at any dose resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital abnormality or birth defect, an important medical event. TEAEs included both serious and non-serious AEs.

    Time frame: From start of study drug administration up to Week 16

  6. Plasma Concentrations of NDI-034858 in Participants Receiving Active Treatment

    The analysis of NDI-034858 levels in plasma was performed using a validated reversed-phase Ultra High-Performance Liquid Chromatography coupled with tandem mass-spectrometry (UHPLC-MS/MS) method. Here, plasma concentrations of NDI-034858 determined at given timepoints were reported.

    Time frame: Week 1: Day 1, Pre-dose and 1-hour post-dose; Week 4: Pre-dose, 1-hour and 4 hours post-dose; Week 8: Pre-dose; Week 12: Post-dose

07

Results

Posted Sep 28, 2023

Participant flow

This study was conducted at 55 study centers in the United States and Canada from 11 August 2021 to 12 September 2022.

Participant flow — Overall Study
MilestonePlaceboNDI-034858 2 mgNDI-034858 5 mgNDI-034858 15 mgNDI-034858 30 mg
Started5250525352
Completed4342454647
Not completed98775
Withdrew: Adverse event11111
Withdrew: Lost to follow-up20241
Withdrew: Withdrawal by subject65322
Withdrew: Lack of efficacy01000
Withdrew: Physician decision00001
Withdrew: Sponsor request01000
Withdrew: Other00100

Outcome measures

PrimaryPercentage of Participants Who Achieved at Least 75 Percent (%) Improvement From Baseline in Psoriasis Area and Severity Index (PASI-75) at Week 12

The PASI quantifies the severity of a participant's psoriasis based on both "lesion severity" and the "percent of body surface area (BSA)" affected. PASI is a composite scoring by the investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk \[including axillae and groin\], and lower limbs \[including buttocks\]), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI composite score varies in increments of 0.1 and range from 0 (no disease) to 72 (maximal disease), with higher scores representing greater severity of psoriasis. PASI 75 response is a binary measure defined as at least a 75% improvement in PASI score at Week 12, relative to baseline PASI score.

Time frame:
Baseline, Week 12
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved at Least 75 Percent (%) Improvement From Baseline in Psoriasis Area and Severity Index (PASI-75) at Week 12
percentage of participantsPlaceboNDI-034858 2 mgNDI-034858 5 mgNDI-034858 15 mgNDI-034858 30 mg
Percentage of Participants Who Achieved at Least 75 Percent (%) Improvement From Baseline in Psoriasis Area and Severity Index (PASI-75) at Week 125.818.044.267.967.3
Statistical analysis
  • Placebo vs NDI-034858 2 mg · Cochran-Mantel-Haenszel · p = =0.052 (P-value was calculated using a Cochran-Mantel-Haenszel (CMH) test, with prior treatment with biologics included as a stratification factor, comparing the percentage of participants in each dose of NDI-034858 vs placebo.) · Odds ratio (or): 3.727 · 95% CI 0.933 to 14.885Odds ratio for achievement of PASI-75 was calculated using the Mantel-Haenszel (MH) method.
  • Placebo vs NDI-034858 5 mg · Cochran-Mantel-Haenszel · p = <0.001 (P-value was calculated using a CMH test, with prior treatment with biologics included as a stratification factor, comparing the percentage of participants in each dose of NDI-034858 vs placebo.) · Odds ratio (or): 12.733 · 95% CI 3.525 to 45.994Odds ratio for achievement of PASI-75 was calculated using the MH method.
  • Placebo vs NDI-034858 15 mg · Cochran-Mantel-Haenszel · p = <0.001 (P-value was calculated using a CMH test, with prior treatment with biologics included as a stratification factor, comparing the percentage of participants in each dose of NDI-034858 vs placebo.) · Odds ratio (or): 29.014 · 95% CI 8.526 to 98.735Odds ratio for achievement of PASI-75 was calculated using the MH method.
  • Placebo vs NDI-034858 30 mg · Cochran-Mantel-Haenszel · p = <0.001 (P-value was calculated using a CMH test, with prior treatment with biologics included as a stratification factor, comparing the percentage of participants in each dose of NDI-034858 vs placebo.) · Odds ratio (or): 40.111 · 95% CI 10.277 to 156.548Odds ratio for achievement of PASI-75 was calculated using the MH method.
SecondaryPercentage of Participants Who Achieved Physician's Global Assessment (PGA) Score of Clear (0) or Almost Clear (1) at Week 12

The PGA is a global assessment of the current state of the disease. It is a 5-point morphological assessment of overall disease severity with scores ranging from 0 to 4, where Score 0: Clear (No signs of psoriasis; post-inflammatory hyperpigmentation may be present); Score 1: Almost clear (No thickening; normal to pink coloration; no to minimal focal scaling); Score 2: Mild (Just detectable to mild thickening; pink to light red coloration; predominantly fine scaling); Score 3: Moderate (Clearly distinguishable to moderate thickening; dull to bright red; clearly distinguishable to moderate erythema; moderate scaling); Score 4: Severe (Severe thickening with hard edges; bright to deep dark red coloration; severe/coarse scaling covering almost all or all lesions). The percentage of participants who achieved a PGA score of clear (0) or almost clear (1) at Week 12 were reported.

Time frame:
At Week 12
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved Physician's Global Assessment (PGA) Score of Clear (0) or Almost Clear (1) at Week 12
percentage of participantsPlaceboNDI-034858 2 mgNDI-034858 5 mgNDI-034858 15 mgNDI-034858 30 mg
Percentage of Participants Who Achieved Physician's Global Assessment (PGA) Score of Clear (0) or Almost Clear (1) at Week 123.810.026.949.151.9
SecondaryPercentage of Participants Who Achieved at Least 90% Improvement From Baseline in Psoriasis Area and Severity Index (PASI-90) at Week 12

The PASI quantifies the severity of a participant's psoriasis based on both "lesion severity" and the "percent of BSA" affected. PASI is a composite scoring by the investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk \[including axillae and groin\], and lower limbs \[including buttocks\]), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI composite score varies in increments of 0.1 and range from 0 (no disease) to 72 (maximal disease), with higher scores representing greater severity of psoriasis. PASI 90 response is a binary measure defined as at least a 90% improvement in PASI score at Week 12, relative to baseline PASI score.

Time frame:
Baseline, Week 12
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved at Least 90% Improvement From Baseline in Psoriasis Area and Severity Index (PASI-90) at Week 12
percentage of participantsPlaceboNDI-034858 2 mgNDI-034858 5 mgNDI-034858 15 mgNDI-034858 30 mg
Percentage of Participants Who Achieved at Least 90% Improvement From Baseline in Psoriasis Area and Severity Index (PASI-90) at Week 1208.021.245.346.2
SecondaryPercentage of Participants Who Achieved at Least 100% Improvement From Baseline in Psoriasis Area and Severity Index (PASI-100) at Week 12

The PASI quantifies the severity of a participant's psoriasis based on both "lesion severity" and the "percent of BSA" affected. PASI is a composite scoring by the investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk \[including axillae and groin\], and lower limbs \[including buttocks\]), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI composite score varies in increments of 0.1 and range from 0 (no disease) to 72 (maximal disease), with higher scores representing greater severity of psoriasis. PASI 100 response is a binary measure defined as at least a 100% improvement in PASI score at Week 12, relative to baseline PASI score.

Time frame:
Baseline, Week 12
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved at Least 100% Improvement From Baseline in Psoriasis Area and Severity Index (PASI-100) at Week 12
percentage of participantsPlaceboNDI-034858 2 mgNDI-034858 5 mgNDI-034858 15 mgNDI-034858 30 mg
Percentage of Participants Who Achieved at Least 100% Improvement From Baseline in Psoriasis Area and Severity Index (PASI-100) at Week 1202.09.615.132.7
SecondaryChange From Baseline in Dermatology Life Quality Index (DLQI) Total Score at Week 12

The DLQI is a simple 10 question validated questionnaire that has been used in more than 40 different skin conditions. The DLQI is the most frequently used quality of life instrument in studies of randomized controlled trials in dermatology. Each question is scored on a four-point Likert scale: very much (3); a lot (2); a little (1); not at all (0). DLQI total score is defined as the sum of the 10 questions, ranging from 0 (not at all) to 30 (very much). Higher scores indicate more impact on quality of life of participants; and lower scores indicate less impact on the quality of life of participants.

Time frame:
Baseline, Week 12
Reported as:
Least squares mean · score on a scale
Change From Baseline in Dermatology Life Quality Index (DLQI) Total Score at Week 12
score on a scalePlaceboNDI-034858 2 mgNDI-034858 5 mgNDI-034858 15 mgNDI-034858 30 mg
Change From Baseline in Dermatology Life Quality Index (DLQI) Total Score at Week 12-4.9 ± 0.75-5.3 ± 0.78-7.9 ± 0.75-8.5 ± 0.74-8.9 ± 0.75
SecondaryNumber of Participants With Treatment-emergent Adverse Event (TEAEs) and Serious TEAEs

An adverse event (AE) means any untoward medical occurrence in a participant administered a pharmaceutical product; the untoward medical occurrence does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product whether or not it is related to the medicinal product. TEAEs were defined as any AEs with onset date on or after the first study treatment dosing. An SAE was any untoward medical occurrence that at any dose resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital abnormality or birth defect, an important medical event. TEAEs included both serious and non-serious AEs.

Time frame:
From start of study drug administration up to Week 16
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Adverse Event (TEAEs) and Serious TEAEs
ParticipantsPlaceboNDI-034858 2 mgNDI-034858 5 mgNDI-034858 15 mgNDI-034858 30 mg
Participants with TEAEs2331282831
Participants with Serious TEAEs00010
SecondaryPlasma Concentrations of NDI-034858 in Participants Receiving Active Treatment

The analysis of NDI-034858 levels in plasma was performed using a validated reversed-phase Ultra High-Performance Liquid Chromatography coupled with tandem mass-spectrometry (UHPLC-MS/MS) method. Here, plasma concentrations of NDI-034858 determined at given timepoints were reported.

Time frame:
Week 1: Day 1, Pre-dose and 1-hour post-dose; Week 4: Pre-dose, 1-hour and 4 hours post-dose; Week 8: Pre-dose; Week 12: Post-dose
Reported as:
Geometric mean · nanograms per milliliter
Plasma Concentrations of NDI-034858 in Participants Receiving Active Treatment
nanograms per milliliterNDI-034858 2 mgNDI-034858 5 mgNDI-034858 15 mgNDI-034858 30 mg
Week 1, Day 1: Pre-dose0.50 ± 0.00.50 ± 0.00.50 ± 0.00.50 ± 0.0
Week 1, Day 1: 1 hour Post-dose0.69 ± 63.71.85 ± 247.72.04 ± 447.73.59 ± 810.5
Week 4: Pre-dose7.38 ± 146.816.22 ± 246.855.87 ± 224.482.81 ± 658.3
Week 4: 1 hour Post-dose8.45 ± 140.721.04 ± 167.864.28 ± 227.6114.95 ± 322.8
Week 4: 4 hours Post-dose12.39 ± 126.033.87 ± 128.3115.04 ± 191.6222.25 ± 215.8
Week 8: Pre-dose7.31 ± 169.411.54 ± 239.759.94 ± 193.0103.82 ± 367.6
Week 12: Post-dose4.66 ± 182.913.06 ± 204.646.92 ± 357.155.51 ± 1473.5

Adverse events

Collected over From start of study drug administration up to Week 16. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/52 (0%)0/52 (0%)9/52 (17.3%)
NDI-034858 2 mg0/50 (0%)0/50 (0%)16/50 (32%)
NDI-034858 5 mg0/52 (0%)0/52 (0%)10/52 (19.2%)
NDI-034858 15 mg0/53 (0%)1/53 (1.9%)16/53 (30.2%)
NDI-034858 30 mg0/52 (0%)0/52 (0%)15/52 (28.8%)
Most frequent serious events
Most frequent serious events
EventPlaceboNDI-034858 2 mgNDI-034858 5 mgNDI-034858 15 mgNDI-034858 30 mg
Pericardial effusionCardiac disorders0/520/500/521/530/52
Pleural effusionRespiratory, thoracic and mediastinal disorders0/520/500/521/530/52
Most frequent other events
Most frequent other events
EventPlaceboNDI-034858 2 mgNDI-034858 5 mgNDI-034858 15 mgNDI-034858 30 mg
COVID-19Infections and infestations1/526/504/526/537/52
Alanine aminotransferase increasedInvestigations0/523/500/520/531/52
DiarrhoeaGastrointestinal disorders1/523/501/521/530/52
Blood creatine phosphokinase increasedInvestigations2/522/502/523/533/52
Dermatitis acneiformSkin and subcutaneous tissue disorders0/520/501/521/533/52
Lymphocyte count decreasedInvestigations0/522/503/522/532/52
LymphopeniaBlood and lymphatic system disorders3/520/500/521/530/52
NeutropeniaBlood and lymphatic system disorders3/522/500/520/531/52
AcneSkin and subcutaneous tissue disorders0/520/501/523/532/52

Baseline characteristics

The modified intent-to-treat (mITT) analysis set included all participants who were randomized and received at least one dose of study treatment.

Age, Continuous
Age, Continuous(years)PlaceboNDI-034858 2 mgNDI-034858 5 mgNDI-034858 15 mgNDI-034858 30 mgTotal
Mean48.8 ± 12.7045.8 ± 14.1745.1 ± 13.6046.2 ± 13.0248.5 ± 11.4146.9 ± 12.99
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboNDI-034858 2 mgNDI-034858 5 mgNDI-034858 15 mgNDI-034858 30 mgTotal
Female211211191982
Male3138413433177
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PlaceboNDI-034858 2 mgNDI-034858 5 mgNDI-034858 15 mgNDI-034858 30 mgTotal
Hispanic or Latino262112191593
Not Hispanic or Latino2629403437166
Unknown or Not Reported000000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PlaceboNDI-034858 2 mgNDI-034858 5 mgNDI-034858 15 mgNDI-034858 30 mgTotal
American Indian or Alaska Native101125
Asian5372320
Native Hawaiian or Other Pacific Islander000000
Black or African American2443417
White4443404642215
More than one race000112
Unknown or Not Reported000000
Psoriasis Area and Severity Index (PASI)
Psoriasis Area and Severity Index (PASI)(score on a scale)PlaceboNDI-034858 2 mgNDI-034858 5 mgNDI-034858 15 mgNDI-034858 30 mgTotal
Mean18.27 ± 8.12018.37 ± 6.75218.60 ± 6.05015.52 ± 4.50417.63 ± 6.22017.67 ± 6.477
Dermatology Life Quality Index (DLQI)
Dermatology Life Quality Index (DLQI)(score on a scale)PlaceboNDI-034858 2 mgNDI-034858 5 mgNDI-034858 15 mgNDI-034858 30 mgTotal
Mean12.4 ± 7.0410.3 ± 6.1912.8 ± 7.4511.9 ± 7.1012.5 ± 6.8712.0 ± 6.95
08

Study locations

69 sites
  • Nimbus site 137
    Birmingham, Alabama 35205, United States
  • Nimbus site 156
    Birmingham, Alabama 35244, United States
  • Nimbus site 132
    Scottsdale, Arizona 85255, United States
  • Nimbus site 133
    Bryant, Arkansas 72022, United States
  • Nimbus site 134
    Fountain Valley, California 92708, United States
  • Nimbus site 108
    Los Angeles, California 90033, United States
  • Nimbus site 124
    Sacramento, California 95816, United States
  • Nimbus site 153
    San Diego, California 92122, United States
  • Nimbus site 111
    San Diego, California 92123, United States
  • Nimbus site 148
    Santa Rosa, California 95405, United States
  • Nimbus site 120
    Sherman Oaks, California 91403, United States
  • Nimbus site 155
    Doral, Florida 33122, United States
  • Nimbus site 149
    Hialeah, Florida 33012, United States
  • Nimbus site 130
    Largo, Florida 33770, United States
  • Nimbus site 160
    Margate, Florida 33063, United States
  • Nimbus site 107
    Miami Lakes, Florida 33014, United States
  • Nimbus site 139
    Miami Lakes, Florida 33014, United States
  • Nimbus site 118
    Ocala, Florida 34470, United States
  • Nimbus site 157
    Sweetwater, Florida 33172, United States
  • Nimbus site 101
    Tampa, Florida 33607, United States
  • Nimbus site 102
    Tampa, Florida 33613, United States
  • Nimbus site 116
    West Palm Beach, Florida 33406, United States
  • Nimbus site 147
    Columbus, Georgia 31904, United States
  • Nimbus site 150
    Macon, Georgia 31217, United States
  • Nimbus site 119
    Sandy Springs, Georgia 30328, United States
  • Nimbus site 123
    Skokie, Illinois 60077, United States
  • Nimbus site 159
    Clarksville, Indiana 47129, United States
  • Nimbus site 140
    Indianapolis, Indiana 46250, United States
  • Nimbus site 154
    Overland Park, Kansas 66210, United States
  • Nimbus site 161
    Louisville, Kentucky 40217, United States
  • Nimbus site 105
    Louisville, Kentucky 40241, United States
  • Nimbus site 136
    Lake Charles, Louisiana 70605, United States
  • Numbus site 114
    Metairie, Louisiana 70006, United States
  • Nimbus site 122
    Rockville, Maryland 20850, United States
  • Nimbus site 115
    Beverly, Massachusetts 01915, United States
  • Nimbus site 135
    Quincy, Massachusetts 02169, United States
  • Nimbus site 146
    Ann Arbor, Michigan 48103, United States
  • Nimbus site 103
    Bay City, Michigan 48706, United States
  • Nimbus site 112
    Troy, Michigan 48084, United States
  • Nimbus site 138
    Troy, Michigan 48084, United States
  • Nimbus site 158
    New Brighton, Minnesota 55112, United States
  • Nimbus site 143
    New York, New York 10075, United States
  • Nimbus site 129
    Charlotte, North Carolina 28277, United States
  • Nimbus site 106
    Wilmington, North Carolina 28405, United States
  • Nimbus site 127
    Bexley, Ohio 43209, United States
  • Nimbus site 145
    Columbus, Ohio 43213, United States
  • Nimbus site 128
    Fairborn, Ohio 45324, United States
  • Nimbus site 141
    Norman, Oklahoma 73071, United States
  • Nimbus site 125
    Pittsburgh, Pennsylvania 15123, United States
  • Nimbus site 110
    Charleston, South Carolina 29407, United States
  • Nimbus site 117
    Jackson, Tennessee 38305, United States
  • Nimbus site 121
    Nashville, Tennessee 37215, United States
  • Nimbus site 109
    Arlington, Texas 76011, United States
  • Nimbus site 113
    Bellaire, Texas 77401, United States
  • Nimbus site 131
    Katy, Texas 77494, United States
  • Nimbus site 104
    San Antonio, Texas 78213, United States
  • Nimbus site 152
    San Antonio, Texas 78229, United States
  • Nimbus site 162
    Webster, Texas 77598, United States
  • Nimbus site 142
    Spokane, Washington 99026, United States
  • Nimbus site 204
    Calgary, Canada
  • Nimbus site 206
    Calgary, Canada
  • Nimbus site 212
    Edmonton, Canada
  • Nimbus site 209
    Hamilton, Canada
  • Nimbus site 203
    Markham, Canada
  • Nimbus site 201
    Montréal, Canada
  • Nimbus site 205
    Oshawa, Canada
  • Nimbus site 210
    Peterborough, Canada
  • Nimbus site 208
    Red Deer, Canada
  • Nimbus site 202
    Waterloo, Canada
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Access criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/ For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2021 to primary completion in Aug 2022, 12 months.

Results were first posted in Sep 2023, 1 year 1 month after primary completion.

Of 146 industry-sponsored phase 2 interventional studies under Psoriasis, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 20. This study's 12 months is close to that.

Counting every sponsor, half of 175 studies reached it within 14 months; a quarter within 9 and three quarters within 23.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 19, 2021
First posted
Aug 11, 2021
StartActual
Aug 11, 2021
Primary completionActual
Aug 19, 2022
CompletionActual
Sep 12, 2022
Results first posted
Sep 28, 2023
Last update
Sep 28, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 28, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04999839
Lead sponsor
Takeda
Collaborators
Innovaderm Research Inc., Nimbus Lakshmi, Inc.
Responsible party
Sponsor
First posted
Aug 11, 2021
Start date
Aug 11, 2021
Primary completion
Aug 19, 2022
Completion
Sep 12, 2022
Results posted
Sep 28, 2023
Last update
Sep 28, 2023

Study contacts

Study Director
study director · Takeda

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Zasocitinib

Start the discussion